WHO 2025 global tuberculosis report 2025 key data analysis for the world and China

doi:10.19871/j.cnki.xfcrbzz.2025.06.001

Abstract

Abstract: The WHO Global Tuberculosis Report 2025 shows that there were 10.7 million new tuberculosis(TB) cases globally in 2024, with China accounting for approximately 6.5% of global incidence, ranking 4th among the 30 high TB burden countries. Global TB deaths totaled approximately 1.23 million, with China making significant progress in mortality control. In 2024, there were approximately 390 000 cases of multidrug-resistant/rifampicin-resistant TB globally; of these, China had about 27 700 cases. From 2015 to 2024, TB incidence cumulatively decreased by 12%, and deaths decreased by 29%, but approximately 47% of TB patients and their families still face catastrophic expenditures. This falls significantly short of the World Health Organization End TB Strategy milestone targets of "reducing TB incidence by 50% and mortality by 75% by 2025 compared to 2015." In 2024, 8.3 million TB patients were newly diagnosed and reported globally, the highest number since WHO began monitoring global TB data, but approximately 2.4 million fewer than estimated, reflecting challenges in case detection and reporting. Although global TB diagnostic and treatment services show recovery trends after the COVID-19 pandemic, new challenges such as reduced international aid funding remain. World Health Organization calls on countries to further increase investment in TB, promote preventive treatment, and expand the application of innovative tools. Based on global data, China has made breakthrough progress in improving coverage of rapid diagnostic technologies and expanding preventive treatment, but monitoring of drug-resistant TB and effective control of medical expenditures still need strengthening. To achieve the strategic goal of "ending TB by 2035," future efforts require deepened collaborative cooperation among multiple sectors including health, education, justice, social security, and civil affairs to form long-term governance synergy and jointly promote systematic and sustainable development of TB prevention and control.

Key words: Tuberculosis, Report, End Tuberculosis Strategy, Burden of disease, World Health Organization

CLC Number:

R521
R563

He Huawei, Huang Aichun, Li Wei, Jiang Changyue, Xu Chaoyan, Meng Xiayan, Li Zhifeng, Huang Xianzhen, Zhu Qingdong, Fu Liang, Lu Puxuan, Xie Zhouhua. WHO 2025 global tuberculosis report 2025 key data analysis for the world and China[J]. Electronic Journal of Emerging Infectious Diseases, 2025, 10(6): 1-9.

References

[1] WORLD HEALTH ORGANIZATION. Global tuberculosis report2025[EB/OL].[2025-11-12]. https://www.who.int/publications/i/item/9789240116924.
[2] CHURCHYARD G, KIM P, SHAH NS, et al.What We Know About Tuberculosis Transmission: An Overview[J]. Infect Dis, 2017, 216(suppl_6):S629-S635.
[3] BAGCCHI S.WHO's Global Tuberculosis Report 2022[J]. Lancet Microbe, 2023, 4(1):e20.
[4] 卢春容, 谭卫国, 陆普选, 等. 2023年WHO全球结核病报告:全球与中国关键数据分析[J/CD].新发传染病电子杂志, 2023, 8(6): 73-78.
[5] KANT S, TYAGI R.The impact of COVID-19 on tuberculosis: challenges and opportunities[J]. Ther Adv Infect Dis, 2021, 8:20499361211016973.
[6] MAO X, WANG J, XU J, et al. Current diagnosing strategies for Mycobacterium tuberculosis and its drug resistance: a review[J]. Appl Microbiol, 2025, 136(5):lxaf100.
[7] REID M, ROBERTS G, GOOSBY E, et al.Monitoring Universal Health Coverage (UHC) in high Tuberculosis burden countries: Tuberculosis mortality an important tracer of UHC service coverage[J]. PLoS One, 2019, 14(10):e0223559.
[8] 余卫业, 谭卫国, 罗一婷, 等. 2018WHO全球结核报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2018, 3(4): 228-233.
[9] 任坦坦, 陆普选, 邓国防, 等. 2020 WHO全球结核报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2020, 5(4): 280-284.
[10] 卢春容, 房宏霞, 陆普选, 等. WHO 2021年全球结核病报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2021, 6(4): 368-372.
[11] 宋敏, 陆普选, 方伟军, 等. 2022年WHO全球结核病报告:全球与中国关键数据分析[J/CD]. 新发传染病电子杂志, 2023, 8(1): 87-92.
[12] JEON SM, KIM TH, LEE S, et al.Research and International Cooperation for Shortening the Treatment Duration of Tuberculosis[J]. Jugan Geongang Gwa Jilbyeong, 2025, 18(11 Suppl):102-118.
[13] SHIN E, KIM SM, YUN JS, et al. Status of Tuberculosis Vaccines Development in Clinical Trials[J]. Jugan Geongang Gwa Jilbyeong, 2025, 18(11 Suppl):88-101. Korean.
[14] ALBERTO NR, ALBERTO IRI, AGRIPO IK, et al.Policy analysis on drug-resistant tuberculosis in ASEAN member countries using a governance framework approach: a scoping review[J]. BMJ Glob Health, 2025, 10(11):e016346.
[15] MUHIE NS. Incidence Rate, Survival Rate,Predictors for Virological Failure Among Adult TB/HIV Coinfected Clients[J]. Trop Med, 2025, 2025:2011556.
[16] LI J, WU W, FANG Z, et al.Diagnostic assistance method for RR-TB/MDR-TB patients under treatment based on CNN-LSTM[J]. Sci Rep, 2025, 15(1):38035.
[17] WORLD HEALTH ORGANIZATION.The second United Nations high-level meeting on TB: new global pledge to end the TB epidemic[EB/OL].[2023-11-10].https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/featured-topics/un-declaration-on-tb.
[18] AN Y, NI R, ZHUANG L, et al.Tuberculosis vaccines and therapeutic drug: challenges and future directions[J]. Mol Biomed, 2025, 6(1):4.
[19] TAIT DR, HATHERILL M, VAN DER MEEREN O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis[J]. N Engl J Med, 2019, 381(25):2429-2439.
[20] ISKANDAR D, SUWANTIKA AA, PRADIPTA IS, et al.Clinical and economic burden of drug-susceptible tuberculosis in Indonesia[J]. Lancet Glob Health, 2023, 11(1):e117-e125.